Quarterly report pursuant to Section 13 or 15(d)

Summary of Significant Accounting Policies (Tables)

v3.2.0.727
Summary of Significant Accounting Policies (Tables)
6 Months Ended
Jun. 30, 2015
Accounting Policies [Abstract]  
Research and development expenses and reimbursements due
Such reimbursements were recognized under the collaboration arrangement with R-Pharm during the three and six months ended June 30, 2015. Information about the Company’s research and development expenses and reimbursements due under collaboration arrangements for the three and six months ended June 30, 2015 and 2014, is presented as follows:
 
 
Three months ended June 30,
 
Six months ended June 30,
 
 
2015
 
2014
 
2015
 
2014
Research and development expense, gross
 
$
3,820

 
$
1,823

 
7,801

 
3,143

Less: Reimbursement of research and development expense
 
538

 

 
732

 

Research and development expense, net of reimbursements
 
$
3,282

 
$
1,823

 
7,069

 
3,143